AI for Life Sciences

Dana Solutions is a pioneer in the application of AI for in vitro cell-based assays. We offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.

We also partner with companies in medical devices and biotechnology, as well as academia and government institutions, to develop breakthrough products and enable new scientific discoveries.



Artificial Intelligence for
Phenotypic Modeling
and Drug Testing

PhenoLearn lets scientists create and deploy highly accurate and robust models of cellular and tissue phenotypes using artificial intelligence.

Visit PhenoLearn


Contractility Analysis of
Beating Cardiomyocytes

The Pulse web service lets scientists upload their own videos of beating cardiomyocytes for automated analysis of contractility.

Visit Pulse


Artificial Intelligence for
In Vitro Structural
Toxicity Testing

PhenoTox uses artificial intelligence to capture drug-induced structural changes in images of cell cultures.

Visit PhenoTox


Artificial Intelligence for
Quality Control for
In Vitro Assays

Robust, High-Throughput QC for In Vitro Assays

Visit Auto-QC

Consulting Services

Novel Algorithms

We develop novel algorithms for analyzing biomedical images, videos, and sensor data, tailored to your project requirements.

Product Ready

We develop end-to-end solutions, deployed in your favorite local or cloud-based environment.

Made with Passion

We work as an extended part of your team, and treat every project as if it were one of our own.

Genea Biomedx

Tenaya Therapeutics

Gladstone Institutes


Fountain Therapeutics

Stanford Bioengineering

Enspectra Health

Chronus Health

Advanced Reproductive Care ARC

Managing Members

Kevin Loewke, PhD

Mahnaz Maddah, PhD

News & Events


Dana Solutions to present at Neuroscience 2019

Come see our poster #707 titled "In-Vitro Structural Neurotoxicity Testing Using Deep Convolutional Neural Networks" on Wednesday October 23 at 8am-12pm in McCormick Place Hall A.


Dana Solutions part of HESI U01 award from the FDA to study cardiac failure modes

Dana Solutions announced today that it will receive a subaward from the Health and Environmental Sciences Institute (HESI) as part of a multi-year U01 grant from the FDA.

Contact Us

3505 El Camino Real
Palo Alto, CA 94306